Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Jaros

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Advances in Skin & Wound Care|July 18, 2024
Improving Wound Healing and Infection Control in Long-term Care with Bacterial Fluorescence ImagingMartha R Kelso, Mark Jaros
Current Medical Research and Opinion|October 28, 2015
Efficacy and safety of low-dose SoluMatrix meloxicam in the treatment of osteoarthritis pain: a 12-week, phase 3 studyRoy Altman, Marc Hochberg, Allan Gibofsky, et al.
Journal of Alzheimer'S Disease : JAD|June 7, 2024
Plasma pTau181 Predicts Clinical Progression in a Phase 2 Randomized Controlled Trial of the 11β-HSD1 Inhibitor Xanamem® for Mild Alzheimer's DiseaseJack Taylor, Mark Jaros, Christopher Chen, et al.
Brain Communications|March 2, 2023
Arbaclofen extended-release tablets for spasticity in multiple sclerosis: open-label extension studyDarin T Okuda, Daniel Kantor, Mark Jaros, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentJack Taylor, Paul Rolan, Mark Jaros, et al.
Brain Communications|December 15, 2022
Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trialDarin T Okuda, Daniel Kantor, Mark Jaros, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 13, 2011
Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trialsNicola Coley, Sandrine Andrieu, Mark Jaros, et al.
Parkinsonism & Related Disorders|March 1, 2022
Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studiesOlivier Rascol, Lars Tönges, Tina deVries, et al.
Journal of Pain Research|November 16, 2012
A randomized, multicenter, pilot study comparing the efficacy and safety of a bupivacaine-collagen implant (XaraColl(®)) with the ON-Q PainBuster(®) Post-op Pain Relief System following open gynecological surgerySusan L Cusack, Harold S Minkowitz, Michael Kuss, et al.
Journal of Pain Research|July 14, 2012
Clinical evaluation of XaraColl(®), a bupivacaine-collagen implant, for postoperative analgesia in two multicenter, randomized, double-blind, placebo-controlled pilot studiesSusan L Cusack, Mark Jaros, Michael Kuss, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Advances in Skin & Wound Care|July 18, 2024
Improving Wound Healing and Infection Control in Long-term Care with Bacterial Fluorescence ImagingMartha R Kelso, Mark Jaros
Current Medical Research and Opinion|October 28, 2015
Efficacy and safety of low-dose SoluMatrix meloxicam in the treatment of osteoarthritis pain: a 12-week, phase 3 studyRoy Altman, Marc Hochberg, Allan Gibofsky, et al.
Journal of Alzheimer'S Disease : JAD|June 7, 2024
Plasma pTau181 Predicts Clinical Progression in a Phase 2 Randomized Controlled Trial of the 11β-HSD1 Inhibitor Xanamem® for Mild Alzheimer's DiseaseJack Taylor, Mark Jaros, Christopher Chen, et al.
Brain Communications|March 2, 2023
Arbaclofen extended-release tablets for spasticity in multiple sclerosis: open-label extension studyDarin T Okuda, Daniel Kantor, Mark Jaros, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentJack Taylor, Paul Rolan, Mark Jaros, et al.
Brain Communications|December 15, 2022
Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trialDarin T Okuda, Daniel Kantor, Mark Jaros, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 13, 2011
Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trialsNicola Coley, Sandrine Andrieu, Mark Jaros, et al.
Parkinsonism & Related Disorders|March 1, 2022
Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studiesOlivier Rascol, Lars Tönges, Tina deVries, et al.
Journal of Pain Research|November 16, 2012
A randomized, multicenter, pilot study comparing the efficacy and safety of a bupivacaine-collagen implant (XaraColl(®)) with the ON-Q PainBuster(®) Post-op Pain Relief System following open gynecological surgerySusan L Cusack, Harold S Minkowitz, Michael Kuss, et al.
Journal of Pain Research|July 14, 2012
Clinical evaluation of XaraColl(®), a bupivacaine-collagen implant, for postoperative analgesia in two multicenter, randomized, double-blind, placebo-controlled pilot studiesSusan L Cusack, Mark Jaros, Michael Kuss, et al.
Pageof 3